Improving Cerebral Blood Flow and Cognition in Patients with Cerebral Small Vessel Disease. the ETLAS-2 Trial
A phase 2 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 100 participants.
Also called NCT05173896
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase
- Phase 2
- Enrolled
- 100 participants
- Sponsor
- Registry
-
NCT05173896 -
2020-002329-27
-
- Other papers using this trial's data
- Tadalafil Treatment in Patients With Cerebral Small Vessel Disease: The ETLAS-2 Randomized Clinical Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (anticipated)
- Countries
- Denmark
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT05173896. Randomized; quadruple masking; primary purpose prevention. Start 2022-05-31 (actual); primary completion 2024-09-23 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Improving Cerebral Blood Flow and Cognition in Patients with Cerebral Small Vessel Disease. the ETLAS-2 Trial
- Acronym
- ETLAS2
- Condition
- Cerebral Small Vessel Diseases
- Condition
- Stroke, Ischemic
- Intervention (Drug)
- Tadalafil 20 MG
- Intervention (Drug)
- Placebo
- Lead sponsor
- Christina Kruuse
- Collaborator
- Danish Research Centre for Magnetic Resonance
- Collaborator
- Bispebjerg Hospital
- Collaborator
- Copenhagen University Hospital, Rigshospitalet
- Collaborator
- University of Copenhagen
- Collaborator
- The Novo Nordic Foundation
- Collaborator
- Nordsjaellands Hospital
Record details
- Record id
cardio:ct-nct05173896- Content hash
254214123a07919f6fc575a664b646eb2d3c494f605b2b615d81b5d783490ffc